China April 2026 Reforms Reshape Drug Approval, Pricing, & Access

In April 2026, healthcare policy measures were implemented by the National Health Commission and the National Medical Products Administration, alongside a drug pricing formation mechanism introduced at the state level.

Together, these measures address healthcare delivery, drug pricing, and conditional drug approval procedures.

Tiered Healthcare Measures Focus on System Coordination

The April 6 measures focus on accelerating tiered diagnosis and treatment, with emphasis on coordination across different levels of the healthcare system.

Key elements include:

• Strengthening medical alliances
• Improving prescription circulation
• Coordinating drug supply
• Enhancing management of Chronic diseases
• Developing local access pathways

Collectively, these elements point to a more connected framework for how care is organized and delivered.

Drug Pricing Mechanism Introduces Lifecycle Framework

Attention then shifts to pricing. On April 14, a drug pricing formation mechanism was implemented, extending pricing management across multiple stages of a product’s lifecycle.

The framework includes:

• First-launch pricing for new drugs
• Ongoing price monitoring
• Payment-standard guidance
• Support for high-level innovative drugs with clear clinical value

Conditional Approval Review Procedure for Drugs

The final measure, issued on April 24 by the National Medical Products Administration, focuses on regulatory pathways. It clarifies procedures for conditional drug approval, providing more defined guidance on how applications are submitted and reviewed.

Final Thoughts: Integrated Policy Direction Requires Coordinated Market Strategy

Taken together, the April 2026 policies show how updates to healthcare delivery, pricing frameworks, and regulatory procedures are being implemented in parallel. For overseas manufacturers, this underscores the need to align key elements of market strategy, including:

• Regulatory pathway selection
• Pricing and reimbursement considerations
• Evidence generation and clinical positioning
• Distribution and alignment with the healthcare system

For tailored support on China pharmaceutical regulation, NMPA approval pathways, or pricing and market access strategy, Cisema provides regulatory intelligence and guidance for international manufacturers entering the China market.

Further Information

• Explore our biopharmaceutical regulatory services in China, covering support in clinical development, regulatory strategy and registration pathways, quality and compliance management, and market access strategies

References

• China to Improve Drug Price Formation Mechanism for Reasonable Pricing (NMPA)
• Announcement of the National Medical Products Administration on Issuing the Working Procedures for Review and Approval of Conditional Drug MarketingAuthorization (No. 41, 2026) (NMPA)
• General Office of the State Council Issues Notice on Measures to Accelerate the Establishment of a Tiered Diagnosis and TreatmentSystem (NHCA)